Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma
作者： Jürgen Eberle , Lothar F. Fecker , Amir M. Hossini , Bahtier M. Kurbanov , Henry Fechner
DOI: 10.1111/J.1600-0625.2007.00655.X
关键词:
摘要: In the last decades melanoma incidence has been increasing worldwide, while mortality remained on a high level. Until now, there is no suitable therapy for metastasized melanoma, which could lead to significant increase in overall survival. Apoptosis deficiency supposed be critical factor resistance, and previous work characterized basic mechanisms of apoptosis regulation melanoma. Genes strategies efficient induction cells were identified, are based proapoptotic Bcl-2 proteins (Bcl-x(S), Bcl-x(AK), Bik/Nbk Bax) as well tumor necrosis (TNF)-related death ligands (CD95L/Fas ligand TNF-related apoptosis-inducing ligand, TRAIL). Proapoptotic genes may employed improved gene therapeutic strategies, conditional oncolytic adenoviral vectors.
sci-hub.se 参考文章(142)
Maria von Willebrand, Klaus Kohler, Tuomo Alanko, Marikki Laiho, Olli Saksela, FGF-2 blocks TGF-β1-mediated suppression of Bcl-2 in normal melanocytes Experimental Dermatology. ,vol. 14, pp. 202- 208 ,(2005) , 10.1111/J.0906-6705.2005.00277.X
Elisabeth Heere-Ress, Christiane Thallinger, Trevor Lucas, Hermine Schlagbauer-Wadl, Volker Wacheck, Brett P. Monia, Klaus Wolff, Hubert Pehamberger, Burkhard Jansen, Bcl‐XL is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy International Journal of Cancer. ,vol. 99, pp. 29- 34 ,(2002) , 10.1002/IJC.10248
B M Kurbanov, L F Fecker, C C Geilen, W Sterry, J Eberle, Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene. ,vol. 26, pp. 3364- 3377 ,(2007) , 10.1038/SJ.ONC.1210134
Mahmoud R Hussein, Anna K Haemel, Gary S Wood, Apoptosis and melanoma: molecular mechanisms. The Journal of Pathology. ,vol. 199, pp. 275- 288 ,(2003) , 10.1002/PATH.1300
U Fischer, K Schulze-Osthoff, Apoptosis-based therapies and drug targets Cell Death & Differentiation. ,vol. 12, pp. 942- 961 ,(2005) , 10.1038/SJ.CDD.4401556
Bernard J. Park, Charles K. Brown, Yun Hu, H. Richard Alexander, Jozsef Horti, Sangeeta Raje, William D. Figg, David L. Bartlett, Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. Human Gene Therapy. ,vol. 10, pp. 889- 898 ,(1999) , 10.1089/10430349950018292
A Hamaï, C Richon, F Meslin, F Faure, A Kauffmann, Y Lecluse, A Jalil, L Larue, M F Avril, S Chouaib, M Mehrpour, Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation Oncogene. ,vol. 25, pp. 7618- 7634 ,(2006) , 10.1038/SJ.ONC.1209738
Lorne J Hofseth, S.Perwez Hussain, Curtis C Harris, p53: 25 years after its discovery. Trends in Pharmacological Sciences. ,vol. 25, pp. 177- 181 ,(2004) , 10.1016/J.TIPS.2004.02.009
Douglas Grossman, Jennifer M. McNiff, Fengzhi Li, Dario C. Altieri, Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human Melanoma Journal of Investigative Dermatology. ,vol. 113, pp. 1076- 1081 ,(1999) , 10.1046/J.1523-1747.1999.00776.X
Grazia Graziani, Csaba Szabó, Clinical perspectives of PARP inhibitors Pharmacological Research. ,vol. 52, pp. 109- 118 ,(2005) , 10.1016/J.PHRS.2005.02.013